peter_finan

Karus Therapeutics appoints two heads

pharmafile | October 28, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Peter Finan, Simon Roitt, karus 

UK drug development firm Karus Therapeutics has grown its R&D team via two new appointments in Dr Simon Roitt, who joins as head of clinical development – and Dr Peter Finan as head of biology.

Roitt who joined Karus in August, will implement the company’s clinical development plans and takes 20 years’ of experience in the healthcare sector to the firm with previous senior roles at Roche, GE Healthcare and Biocompatibles International.

Finan (pictured) took up his new position as head of biology in September following an extensive career in the pharma industry. He joins Karus from Novartis, where he held a number of senior roles over a 16-year period. 

Advertisement

Dr Simon Kerry, chief executive of Karus says: “As we develop the business, the recruitment of highly experienced senior talent to our team will be a critical success factor. Simon and Peter both bring valuable clinical and scientific expertise to the Company, to help drive our programmes towards the clinic.”

Roitt adds: “It’s an exciting time to be joining Karus, as the company’s promising pre-clinical programmes move towards human trials. I look forward to contributing to the success of Karus’s clinical programmes.”

Finan concludes: “Having spent much of my recent career working in pharmaceutical R&D, I am looking forward to adding my experience to the excellent progress that Karus has already made in developing highly selective and effective inhibitors against important therapeutic targets, and to bringing best in class drugs to market.”

Related Content

No items found
The Gateway to Local Adoption Series

Latest content